New antibody could tame dual hepatitis b and d infection
NCT ID NCT07610772
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a lab-made antibody (HepB mAb19) in 15 people with chronic hepatitis D, a serious liver infection that requires hepatitis B to survive. The goal is to see if the antibody is safe and can lower virus levels, potentially reducing the risk of liver damage and cancer. Participants will receive two or three doses and be monitored for 60 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aarhus University Hospital
RECRUITINGAarhus, 8000, Denmark
-
Charité - Universitätsmedizin Berlin
NOT_YET_RECRUITINGBerlin, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a daily pill tame hepatitis d?
- Can a new injection tame chronic hepatitis b?
- Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus
- Could common hepatitis b drugs damage kidneys? a study digs into the data